Showing 4011-4020 of 6949 results for "".
- AAD: Research Shows Free Skin Cancer Screenings Can Help Save Liveshttps://practicaldermatology.com/news/aad-research-shows-free-skin-cancer-screenings-can-help-save-lives/2457675/Data indicates that American Academy of Dermatology’s (AAD's) SPOTme program serves an important need. While skin cancer can be deadly, it is also highly treatable when detected early. In fact, melanoma, the deadliest form of skin cancer, has a five-year survival rate of 95 percen
- Can Turning Off a Mutation Causing Wrinkling and Hair Loss Reverse the Processes? New Mouse Model Says Yeshttps://practicaldermatology.com/news/can-turning-off-a-mutation-causing-wrinkling-and-hair-loss-reverse-the-processes-new-mouse-model-says-yes/2457680/A new mouse model may one day allow scientists to reverse age-associated wrinkles and hair loss. When a mutation leading to mitochondrial dysfunction is induced, the mouse develops wrinkled skin and extensive, visible hair loss in a matter of weeks, but when the mitochondrial function is
- Pulse Biosciences: First Patients Treated in Study of Sebaceous Hyperplasia Lesionshttps://practicaldermatology.com/news/pulse-biosciences-first-patients-treated-in-study-of-sebaceous-hyperplasia-lesions/2457682/Pulse Biosciences, Inc. says the first patients have been treated in its multi-center study to evaluate the safety and efficacy of its Nano-Pulse Stimulation (NPS) technology for eliminating Sebaceous Hyperplasia (SH). SH is an unsightly benign skin lesion that typically appears on facial skin an
- Game On: Head-to-head Trials to Enhance Competition in PsO Markethttps://practicaldermatology.com/news/head-to-head-trials-to-enhance-competition-in-pso-market/2457684/An increase in head-to-head trials will enhance the competition within the psoriasis market, according to
- BioPharmX: FDA Grants CARC Waiver; Post-Hoc Analysis for BPX-01 Completehttps://practicaldermatology.com/news/biopharmx-fda-grants-carc-waiver-post-hoc-analysis-for-bpx-01-complete/2457686/The FDA has waived its requirement for a dermal carcinogenicity study for BPX-01 from BioPharmX Corporation, eliminating several years of non-clinical research normally required for FDA review. BPX-01, a novel topical gel formulation of minocycline for the treatment of inflammatory
- Dermatologists, Skin Cancer Survivors Tell "Skin Cancers, Take a Hike!"https://practicaldermatology.com/news/dermatologists-skin-cancer-survivors-tell-skin-cancers-take-a-hike/2457695/To help raise awareness of skin cancer prevention and detection, 12 dermatologists, skin cancer survivors, and their family and friends will tell “Skin Cancer, Take a Hike!” during a four-day trek through remote Alaska. Starting Sunday, July 15, the hikers will trek more than 20 miles
- Sensus Healthcare Forms Strategic Agreement with SkinCure Oncologyhttps://practicaldermatology.com/news/sensus-healthcare-forms-strategic-agreement-with-skincure-oncology/2457697/Sensus Healthcare, Inc., which specializes in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), formed a strategic agreement focused on marketing the SRT-100 Vision with SkinCure Oncology, a leading turnkey provider
- New From InMode: Triton Multi-Wavelength Hair Removal Laserhttps://practicaldermatology.com/news/new-from-inmode-triton-multi-wavelength-hair-removal-laser/2457698/InMode Ltd. is launching the Triton hair removal device. Recently cleared by the FDA, Triton is the first and only high power laser to offer simultaneous multi-wavelength hair removal firing, allowing concurrent emissions of Alexandrite, Diode, and Nd:YAG wavelengths. The company say
- About 415 Million People May Have Rosacea Worldwidehttps://practicaldermatology.com/news/about-415-million-people-may-have-rosacea-worldwide/2457701/As many as 415 million people worldwide may have rosacea, according to new research in the British Journal of Dermatology. Dr. Jacob Thyssen and colleagues at the University of Copenhagen, Denmark, conducted
- FDA Approves Dermira's Qbrexza Cloth to Treat Primary Axillary Hyperhidrosishttps://practicaldermatology.com/news/fda-approves-delmiras-qbrexza-cloth-to-treat-primary-axillary-hyperhidrosis/2457709/The FDA has approved Qbrexza™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Qbrexza is applied directly to the skin and is designed to block sweat production by inhib